About

Who We Are

Rubicon Genomics was founded in 2000 by two University of Michigan faculty members, Dr. John Langmore and Dr. Vladimir Makarov, who wanted to advance the translation of human genetics “laboratory knowledge” into practical medicine applications. The founders also decided to maintain the company’s roots in Michigan with a commitment to supporting the Michigan economy.

Today, Rubicon Genomics is a privately held company located in Ann Arbor, Michigan and employs 20 administrative and technical staff. Our innovative products combined with our strategic partnerships have established the company as a leader in pre-analytical amplification technologies that "break the sample barriers" for our customers. Rubicon sells its products into the research and commercial markets directly and through distributors.

Our Mission

Rubicon Genomics intends to be the premiere provider of technology for the pre-analytical amplification of nucleic acid for research and commercial applications. Rubicon is taking advantage of its technologies’ simple protocols, fast time to results and unique ability to amplify nucleic acid from “difficult” samples to develop differentiated products that enable researchers and healthcare providers to more easily and cost-effictively realize the benefits of the genomic revolution.

Rubicon Genomics' core competencies include enzymology, nucleic acid chemistry, sample processing and manufacturing. Since the founding of the company, these competencies have served as engines for innovation, development of intellectual property, ongoing product development, and a commitment to customer service, resulting in our:

Robust patent portfolio
High impact product pipeline
Industry leading products
Project services
Satisfied customers

We are proud that our kits, services, partnerships and licenses have enabled the discovery of many novel biomarkers and disease genes to date.